[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"embryo-transfer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:embryo-transfer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,55,85,112,147,174,200,228,252,278],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100053246","linzagolix-in-adenomyosis-and-recurrent-implantation-failure-100053246",false,"NCT07698561","Linzagolix in Adenomyosis and Recurrent Implantation Failure","Efficacy of Linzagolix 200 mg for 3 to 6 Months Prior to Embryo Transfer in Patients With Adenomyosis and Recurrent Implantation Failure: A Prospective Case Series","LINZA-RIF","Inclusion Criteria:\n\n* Age 18 to 50 years\n* Confirmed adenomyosis by transvaginal ultrasound or MRI\n* Recurrent implantation failure defined as 2 or more failed embryo transfers with high-quality blastocysts: oocyte donation recipients (blastocyst grade BB or above, Gardner classification) OR autologous IVF cycles with PGT-A confirmed euploid blastocysts\n* Normal uterine cavity with no submucosal distortion\n* At least 1 suitable embryo available for transfer (blastocyst grade BB or above, or PGT-A euploid)\n* Signed written informed consent including explicit acknowledgement of off-label use of linzagolix\n\nExclusion Criteria:\n\n* Untreated hydrosalpinx\n* Untreated stage III-IV endometriosis\n* Major uterine anomaly (uterine septum, bicornuate uterus)\n* Known contraindication to linzagolix including known hepatopathy\n* Prior treatment with linzagolix\n* GnRH analogue treatment within 6 months prior to enrolment\n* BMI greater than 35 kg\u002Fm2\n* Prior failed transfers exclusively with embryos below the quality threshold (below BB grade, non-euploid)","FEMALE","18 Years","50 Years",{"count":21,"type":22},35,"ESTIMATED","2 Years","OBSERVATIONAL","Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos. Linzagolix (Yselty, 200 mg) is an oral GnRH receptor antagonist approved for uterine fibroids with a favourable tolerability profile and rapid elimination half-life (18-20 hours) compared to GnRH agonists.\n\nThis prospective case series evaluates the efficacy of linzagolix 200 mg administered for 3 to 6 months prior to embryo transfer in patients with confirmed adenomyosis and recurrent implantation failure (RIF), defined as ≥2 failed transfers with high-quality blastocysts (≥BB Gardner in oocyte donation, or PGT-A confirmed euploid in autologous cycles).\n\nThe primary endpoint is the live birth rate (LBR) per embryo transfer. Secondary endpoints include clinical pregnancy rate, miscarriage rate, morphological response of adenomyosis (uterine volume and junctional zone \\[JZ\\] thickness assessed by standardised transvaginal ultrasound), and tolerability profile. The study also explores the optimal treatment duration (3 vs 6 months) as a sub-analysis based on morphological response at the month-3 visit.\n\nThe study is conducted at three centres of Vida Fertility Institute (Madrid, Alicante and San Sebastián, Spain). Sample size: n=35 patients. Study duration: 24 months.",[27,28,29,30],"Adenomyosis of Uterus","Implantation Failure","Infertility Female","Embryo Transfer",[32,33,34,35,36,37,38,39,40,41],"Linzagolix","Yselty","adenomyosis","recurrent implantation failure","junctional zone","live birth rate","oocyte donation","PGT-A","GnRH antagonist","endometrial receptivity","NOT_YET_RECRUITING","2026-07-06",{"date":45,"type":46},"2026-07-13","ACTUAL",{"date":48,"type":22},"2026-09-01",{"date":50,"type":22},"2028-09-01",{"name":52,"class":53},"Vida Fertility Institute","INDUSTRY",3,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100573266","transfer-direct-system-as-a-new-method-for-embryo-transfer-100573266","NCT06744049","Transfer Direct System as a New Method for Embryo Transfer","Assessment of Transfer Direct System (TDS) as a New Method for Embryo Transfer","TDS","Inclusion Criteria:\n\n1. Patients whose written informed consent is obtained, approved by the Ethics Committees for Investigation with Medicinal Products (ECRmp) after being duly informed of the nature of their disease and after voluntarily accepting the treatment program, knowing the potential risks, benefits, and inconveniences.\n2. Patients who are going to undergo ART with a SET and have at least one vitrified euploid blastocyst with PGT-A (Preimplantation Genetic Test for the detection of Aneuploidy).\n3. Women of reproductive age between 18 and 50 years (both inclusive)\n4. Body mass index (BMI): \\\u003C30 kg\u002Fm2\n5. Absence of adenomyosis and endometriosis\n6. Uterus without pathologies that can contraindicate the transfer or may hinder implantation (e.g., polyps, fibroids that come into contact with the cavity, or Asherman syndrome) or without a history of thin endometrium or irregular patterns in thin endometrial preparations.\n7. Absence of immune pathologies (e.g., lupus) that could endanger the health of the patient.\n8. Easy transfer test or history of embryo transfer without difficulty or factors that indicate that the transfer is easy.\n\nExclusion Criteria:\n\n1. Difficult or very painful transfer tests.\n2. Pathologies of an oncological nature.\n3. The existence of serious or uncontrolled bacterial, fungal, or viral infections that, in the opinion of the principal investigator, may interfere with the patient's participation in the study or the evaluation of its results.\n4. Other circumstances or difficulties that, in the opinion of the investigator, may pose a risk to the subject or reduce the chances of obtaining satisfactory data to achieve the objectives of the study, such as a history of severe preeclampsia without assessment by the obstetric team, psychiatric pathologies without prior assessment by the psychiatrist, uncontrolled or destabilized cardiac pathologies.",{"count":64,"type":22},80,"INTERVENTIONAL",[67],"NA","Infertility is defined as the inability to conceive within a year of unprotected intercourse. Infertility affects one in six couples and represents a public health problem causing feelings of helplessness, depression, and anxiety in both women and men worldwide. Despite the desire to become parents, up to 50% of infertile couples do not seek medical treatment, and 50-60% abandon treatment after two or three failed in vitro fertilization (IVF) cycles, even when the procedure is covered by insurance or public health. There are multiple reasons for this discontinuation; however, after removing cost considerations, psychological stress and poor prognoses represent the main reasons for stopping treatment.\n\nClinical infertility treatments are generally ineffective. Success remains poor even with IVF, as evidenced by current live birth rates (LBRs) of only \\~30% per initiated cycle. The primary challenge in ART lies mainly in the embryo implantation process, which remains the most significant bottleneck in IVF success, accounting for over 50% of ART failures.\n\nEmbryo transfer (ET), the final step in IVF, has seen little technological advancement since its inception over four decades ago. The procedure is typically performed transcervically and largely relies in tactile sensation and operator's experience. Although a simple procedure, several potential negative factors may be linked to the low number of IVF pregnancies, including variations in catheter placement, the risk of uterine contractions and lack of control of intrauterine pressure and embryo placement can result in up to 15% of the transferred embryos being inadvertently expelled from the uterus. Therfore, ET's success is highly dependent on non-controllable variables as well as the skill and experience of the operator, resulting in significant inter-operator variability.\n\nPremium Fertility team has developed a controlled embryo transfer system - the Transfer Direct System (TDS) - that incorporates a visualization system to guide embryo delivery with the help of a fully automated microfluidic system that avoids initial phases of apposition and adhesion of implantation of human embryos. This technique places the embryo directly in the endometrial tissue, thereby minimizing the effects of embryo expulsion and potentially offering significant advantages such as the ability to visualize the uterine cavity through an endoscope at the time of embryo transfer and control the mechanics of the injection procedure to increase precision.",[30],[71,72],"Semi-automatization","Embryo implantation","RECRUITING","2026-06-22",{"date":76,"type":46},"2026-06-23",{"date":78,"type":46},"2024-10-21",{"date":80,"type":22},"2027-03",{"name":82,"class":83},"Premium Fertility","OTHER",4,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":65,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100631372","phase-3-effect-of-pentoxyfilline-on-endometrial-thickness-and-frozen-embryo-transfer-outcomes-100631372","NCT07499817","Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes","Inclusion Criteria:\n\n* as good quality day five frozen embryos.\n\nExclusion Criteria:\n\n* history of endocrine diseases,\n* history of any previous surgery that couldm compromise the integrity of endometrium,\n* cardiovascular, renal and liver diseases,","43 Years",{"count":93,"type":22},100,[95],"PHASE3","The aim of this work was to investigate the effect of different vasodilators as pentoxifylline in women with unexplained infertility using IVF",[30,98,99],"IVF","Infertility",[101,98],"thawed embryo","2026-03-25",{"date":104,"type":46},"2026-03-30",{"date":106,"type":46},"2023-10-01",{"date":108,"type":22},"2026-04-30",{"name":110,"class":83},"Beni-Suef University",1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":65,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":54},"100410056","biomarkers-of-endometrial-receptivity-100410056","NCT04619524","Biomarkers of Endometrial Receptivity","Biomarkers of Endometrial Receptivity: A Prospective Multicenter Study on Proteomic Biomarkers of Endometrial Receptivity in Cervical Mucus ( PRO BIOMER - CM )","BIOMER","Inclusion Criteria - Arm A - stimulated cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* follicle stimulating hormone (FSH) \\\u003C 10 IU\u002FL on the third day\n* basal antral follicle count of 5-15\n* undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol\n* informed consent\n\nExclusion Criteria - Arm A - stimulated cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria)\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 1.0 mIU\u002Fml or more than 20 oocytes, milli-International unit (mIU)\n* previous ovarian hyperstimulation syndrome (OHSS)\n* presence of any structural abnormality of the reproductive system\n* donor oocyte cycles\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL\n* low response to stimulation\n* endometrium \\\u003C 8 mm at the day of human chorionic gonadotropin (hCG) or ET\n* number of retrieved oocytes 5 - 20\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* OHSS\n* IVF cycle cancelled before ET\n* other than easy one high-quality blastocyst transfer (at least grade 3BB)\n\nInclusion criteria - Arm B - substituted cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder at stimulation\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* FSH \\\u003C 10 IU\u002FL on the third day\n* undergoing the same routine estrogen\u002Fprogesterone substituted cycle\n* informed consent\n\nExclusion criteria - Arm B - substituted cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders such as diabetes, metabolic syndrome, and thyroid disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria), hyperprolactinaemia\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 0.5 mIU\u002Fml in the stimulated cycle\n* previous OHSS\n* presence of any structural abnormality of the reproductive system\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL in the stimulated cycle\n* number of retrieved oocytes 5 - 20 in the stimulated cycle\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* endometrium less than 8 mm at the day of thawing and transfer indication\n* thawed blastocyst cycle cancelled before ET\n* other than easy one best quality frozen\u002Fthawed blastocyst transfer (at least grade 3BB)","36 Years",{"count":122,"type":22},476,[67],"Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.",[98,126,127,30],"Infertility Treatment","Fertility Disorders",[129,130,131,132,133,134,135,136,137],"cervix","mucus","endometrium","receptivity","biomarker","proteomics","infertility","in-vitro","fertilisation","2026-03-19",{"date":140,"type":46},"2026-03-20",{"date":142,"type":46},"2018-05-01",{"date":144,"type":22},"2026-12-31",{"name":146,"class":83},"The Institute of Molecular and Translational Medicine, Czech Republic",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":154,"targetDuration":4,"studyType":65,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":111},"100599781","triggering-ovulation-at-follicle-size-smaller-or-larger-than-17mm-in-a-modified-natural-cycle-100599781","NCT07088952","Triggering Ovulation at Follicle Size Smaller or Larger Than 17mm in a Modified Natural Cycle","17FET","Inclusion Criteria:\n\n* At least one expanded blastocyst (regardless of its quality)\n* Spontaneous menstrual cycles\n* Consent to undergo frozen embryo transfer in a modified natural cycle\n\nExclusion Criteria:\n\n* Abnormal uterine cavity\n* Fluid in endometrial cavity",{"count":155,"type":22},572,[67],"The rise in frozen embryo transfer (FET) cycles within assisted reproductive technology (ART) has sparked the need to refine endometrial preparation protocols. The switch from hormone replacement cycles (HRT) to natural cycles, poses scheduling challenges onto laboratories, doctors and patients. The modified natural cycle (mNC), offering more precision for scheduling, shows promise but lacks comprehensive data on the potential flexibility of triggering criteria that may allow to control timing in a wider range.\n\nThis prospective randomized study seeks to address this knowledge gap by evaluating the non-inferiority of triggering ovulation in mNC with follicle diameters of 13-16.9mm compared to the conventional 17-22mm.\n\nThe study aims to enhance the understanding of the impact of follicle size at ovulation in reproductive outcomes, optimize FET treatments providing a more flexible mNC protocol, and improve patient care in ART clinics.",[30],[160,161,162,163,164],"Natural Cycle","Frozen Embryo Transfer","Follicle Size","Pregnancy","Implantation","2026-01-09",{"date":167,"type":46},"2026-01-13",{"date":169,"type":46},"2025-10-22",{"date":171,"type":22},"2028-05-30",{"name":173,"class":83},"Vida Recoletas Sevilla",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":181,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":65,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100613653","phase-4-dual-trigger-with-hcg-and-gnrh-agonist-on-thawed-modified-natural-cycle-embryo-transfer-100613653","NCT07269392","Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo Transfer","Impact of Dual Trigger Using Recombinant Human Chorionic Gonadotropin (HCG) and Gonadotropin-releasing Hormone (GnRH) Agonist on Thawed Modified Natural Cycle Outcomes: an Open-label Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1\\. 24\\\u003C= Age \\\u003C 45 patient undergo mNC-FET\n\nExclusion Criteria:\n\n1\\. Congenital or acquired uterine abnormalities (uterine malformation, submucosal myoma, intrauterine adhesion or endometrial polyp \\>1cm)",true,"25 Years","44 Years",{"count":185,"type":22},170,[187],"PHASE4","Impact of dual trigger using recombinant human chorionic gonadotropin (HCG) and gonadotropin-releasing hormone (GnRH) agonist on thawed modified natural cycle outcomes: an open-label multi-center randomized controlled trial.",[190,30],"In Vitro Fertilization (IVF)","2025-12-08",{"date":193,"type":46},"2025-12-16",{"date":195,"type":22},"2026-01-01",{"date":197,"type":22},"2029-12-31",{"name":199,"class":83},"National Taiwan University Hospital",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":181,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":65,"phases":210,"briefSummary":211,"conditions":212,"keywords":216,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":227},"100544686","letrozole-stimulated-cycle-strategy-versus-artificial-cycle-strategy-letsact-100544686","NCT06372119","Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)","Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy for Endometrial Preparation in Women With Irregular Menstrual Cycles: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 - 42.\n* Irregular menstrual cycle (\\\u003C 21 days or \\> 35 days or \\\u003C 8 cycles\u002Fyears).\n* Indicated for endometrial preparation.\n* Transfer of only one blastocyst.\n* Not participating in any other trials.\n\nExclusion Criteria:\n\n* Allergy to letrozole or Ovitrelle or oral estradiol valerate or micronized progesterone\n* Having embryos from either oocyte donation or PGT (pre-implantation genetics testings) cycles.\n* Ovarian cysts that are unrelated to the oocyte pick-up.\n* Confirmed diagnosis with recurrent pregnancy loss (RPL) according to ESHRE guideline 2023, recurrent implantation failure (RIF) according to ESHRE 2023 good practice recommendations.\n* Endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, and chronic endometritis.\n* Uterine abnormalities include leiomyomas L0, L1, or L2 (according to FIGO 2011); adenomyosis (according to MUSA 2022); congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate (according to ASRM 2021).\n* Untreated hydrosalpinx.","42 Years",{"count":209,"type":22},790,[67],"The goal of this randomized clinical trial is to evaluate the effectiveness of the letrozole-stimulated cycle strategy versus the artificial cycle strategy for endometrial preparation in women with irregular menstrual cycles after one cycle of endometrial preparation. The primary question it aims to answer is:\n\n• Does the letrozole-stimulated cycle strategy for endometrial preparation result in a higher live birth rate compared to the artificial cycle strategy in women with irregular menstrual cycles after one cycle of endometrial preparation?\n\nParticipants will undergo screening before endometrial preparation for frozen embryo transfer, following which they will be randomly assigned to one of two groups: LETS or AC. In the LETS group, investigators will prescribe letrozole 5 milligrams\u002Fday for 5 days to stimulate follicular development and micronized progesterone 800 milligrams\u002Fday for luteal phase support. In contrast, the AC group will receive oral estradiol valerate 6-12 milligrams\u002Fday and micronized progesterone 800 milligrams\u002Fday. Researchers will compare the LETS and AC groups to determine if there are differences in live birth rates.",[30,213,214,215],"Irregular Menstruation","Letrozole","Hormone Replacement Therapy",[217,213,214,215],"Blastocyst Transfer","2025-09-22",{"date":220,"type":46},"2025-09-25",{"date":222,"type":46},"2024-04-22",{"date":224,"type":22},"2026-04",{"name":226,"class":83},"Mỹ Đức Hospital",2,{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":181,"sex":17,"minAge":18,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":65,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":111},"100584996","phase-4-impact-of-the-presence-of-the-corpus-luteum-on-pregnancies-obtained-through-frozen-embryo-transferfet-100584996","NCT06896617","Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)","Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET): a Prospective Randomized Controlled Study","LUTI","Inclusion Criteria:\n\n* Female patients 18- 37 years old (both included) at the time of oocyte retrieval and less than 41 years of age at the time of embryo transfer.\n* Regular menstrual cycles between 24 and 35 days.\n* Availability of cryopreserved blastocysts from own gametes\n* Indication for single embryo transfer.\n* Patients who will be included in the LUTI study are candidates for either of the two procedures under study, and will have no contraindications for either procedure.\n\nExclusion Criteria:\n\n* Recurrent pregnancy loss (3 or more).\n* Recurrent implantation failure in previous IVF treatments (3 or more unsuccessful embryo transfers). .\n* Diagnosis of polycystic ovarian syndrome, diabetes mellitus, chronic arterial hypertension, maternal heart disease and autoimmune diseases (Systemic Lupus Erythematosus (SLE) or Antiphospholipid syndrome (APS)).\n* Active treatment with aspirin, heparin or other anticoagulant therapy, antihypertensives or other drugs used to treat circulation or coagulation disorders .\n* Indication for PGT (Preimplantation Genetic Testing).\n* Multiple pregnancy.","41 Years",{"count":238,"type":22},334,[187],"In pregnancies achieved through programmed frozen embryo transfer cycle (PC-FET) and modified natural frozen embryo transfer (mNC-FET), to determine whether there are differences in endothelial and placental function, maternal cardiovascular function, fetal growth and fetal cardiovascular and cerebral programming and to assess whether there is an association between these differences and the plasma concentrations of the main secretion products of the Corpus Luteum (CL) with vasoactive and angiogenic action.",[242,30],"Infertilities","2025-03-28",{"date":245,"type":46},"2025-04-02",{"date":247,"type":46},"2025-02-01",{"date":249,"type":22},"2026-12-20",{"name":251,"class":83},"Fundacion Clinic per a la Recerca Biomédica",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":260,"targetDuration":4,"studyType":65,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":111},"100474631","phase-3-treatment-preventive-for-pre-eclampsia-by-acetylsalicylic-acid-in-women-who-underwent-frozen-embryo-transfer-100474631","NCT05460416","Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer","A Prospective Interventional Randomized Controlled Trial to Assess the Effect of Low Dose Acetylsalicylic Acid As a Preventive Treatment of Pre-eclampsia in Pregnant Women Who Underwent Frozen Embryo Transfer","TePPAFET","Inclusion Criteria:\n\n* Healthy women from \\[18 - 43\\] years-old, planned for a frozen embryo transfer, with natural and modified natural or HRT cycle\n* Who have given their informed consent\n* Who have a confirmed pregnancy at week 6 of amenorrhea.\n\nExclusion Criteria:\n\n* Women presenting one risk factor for preeclampsia: multiple pregnancy, history of preeclampsia, BMI \\> 30, lupus syndrome, preexistent proteinuria, non-treated chronic high blood pressure (\\>140\u002F90), antiphospholipid antibody syndrome, diabetes (fasting blood sugar \\>126mg\u002Fdl)\n* Contraindication to acetylsalicylic acid (at risk of active hemorrhage (like hemophilia, …); at risk of or who have a gastro-duodenal ulcer; at risk or how have a terminal renal or hepatic in-sufficiency (only if acetylsalicylic acid is given at high dose)\n* Already treated with acetylsalicylic acid\n* Treatment with anticoagulants or non-steroid anti-inflammatory drugs",{"count":261,"type":22},276,[95],"Title: A prospective multicentric interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of pre-eclampsia in pregnant women who underwent frozen embryo transfer",[30,265],"Hypertension, Pregnancy Induced",[267,268],"embryo transfer","Hypertension, Pregnancy induced","2025-02-14",{"date":271,"type":46},"2025-02-18",{"date":273,"type":46},"2022-10-25",{"date":275,"type":22},"2026-06-30",{"name":277,"class":83},"Centre Hospitalier Universitaire de Liege",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":181,"sex":17,"minAge":18,"maxAge":236,"enrollmentInfo":285,"targetDuration":4,"studyType":65,"phases":287,"briefSummary":288,"conditions":289,"keywords":292,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":111},"100526428","does-sexual-intercourse-affect-the-outcomes-of-frozen-thawed-embryo-transfer-100526428","NCT06134609","Does Sexual Intercourse Affect the Outcomes of Frozen-thawed Embryo Transfer?","Does Sexual Intercourse Affect the Outcomes of Frozen-thawed Embryo Transfer? Randomized Controlled Trial","Inclusion Criteria:\n\n1. Women age 18-41yrs.\n2. BMI (body mass index) of 18-35 kg\u002Fm².\n3. Patients undergoing one of their first four frozen embryo transfers.\n4. Patients transferring a good quality embryo, either a cleavage stage embryo or a day 5 blastocyst.\n\nExclusion Criteria:\n\n1. Patients age above 42.\n2. Moderate or poor-quality embryos.\n3. Patients with hydrosalpinx or uterus malformations.\n4. Patients who are not able or are not interested in having vaginal intercourse (same sex couples for example).\n5. Couples undergoing preimplantation genetic diagnosis when natural cycle frozen embryo transfer is planned (as they are instructed to avoid intercourse).",{"count":286,"type":22},656,[67],"The goal of this clinical trial is to test whether sexual intercourse the night after embryo transfer affects thawed embryo implantation rates. Women undergoing one of their first four frozen embryo transfers with a good quality embryo will be randomly assigned to two groups. The study group is subjected to have intercourse without using a condom at the evening\u002Fnight after the embryo transfer, while the control group will abstain from intercourse for the next 48 hours after the transfer. Researchers will compare the ongoing pregnancy rates between the intervention group and the control group.",[30,290,291],"Fertilization in Vitro","Coitus",[98,30,293,291,163],"Sexual intercourse","2023-11-16",{"date":296,"type":46},"2023-11-18",{"date":298,"type":46},"2023-11-13",{"date":300,"type":22},"2026-11",{"name":302,"class":303},"Sheba Medical Center","OTHER_GOV"]